Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Activity of C2L-OCT-01 PR in Acromegaly
NCT00642421Phase 3Terminated
- Sponsor
- Ambrilia Biopharma Inc.
- Start
- Feb 2008
- Primary completion
- Aug 2009
- Modality
- Peptides
- Countries
- 6
01
Overview
Phase 3, open-label trial of octreotide in acromegaly (2 arms), sponsored by Ambrilia Biopharma Inc. Primary endpoint: Safety profile of C2L-OCT-01 PR at 58 weeks. Started Feb 2008; status: terminated.
02
Drugs
octreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT00642421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00642421.